Navigating Risks and Rewards- Immunotherapies in Myeloma Care | Adam Cohen, MD

Adam Cohen, Director of Myeloma Immunotherapy at the University of Pennsylvania, discusses how patients and doctors can balance the risks and benefits of immunotherapy when treating relapsed or refractory multiple myeloma.

Dr. Cohen explains what factors to consider when choosing between available immunotherapies — including CAR T-cell therapy, bispecific antibodies, and other novel treatments. Learn how side effects, treatment goals, prior therapies, and personal preferences all play a role in finding the best fit for each patient.